Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Select a campus/region

HIIT following breast cancer chemotherapy

  • Status
    Accepting Candidates
  • Age
    18 Years - 85 Years
  • Sexes
  • Healthy Volunteers


Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.


Full study title High Intensity Interval Training: Optimizing Exercise Therapy to Mitigate Cardiovascular Disease Risk Following Breast Cancer Chemotherapy
Protocol number OCR44206 ID NCT05913713
Phase N/A


Inclusion Criteria:

  • female patients based on biological sex

  • 18 to 85 years of age

  • diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer

  • completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 12 months prior to study enrollment

  • absence of contraindications to exercise or to participate in study

  • study clinician approval

Exclusion Criteria:

  • do not meet inclusion criteria

  • completed chemotherapy and/or other cancer treatment (e.g., surgery or radiation) besides ovarian suppression within 6 months of study enrollment

  • scheduled to receive surgery, radiation therapy or other cancer treatment besides ovarian suppression during the study period

  • lymphedema stage ≥2 prior to study enrollment

  • any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)

  • are pregnant

  • current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

  • consistent participation over the past 6 months in moderate-intensity aerobic exercise training for ≥150 min/week

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

    Danielle Ogden
  2. Step

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step


    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.